KR20050108383A - 이소퀴놀린 유도체의 암 및 map 키나제 관련 질병의치료를 위한 용도 - Google Patents

이소퀴놀린 유도체의 암 및 map 키나제 관련 질병의치료를 위한 용도 Download PDF

Info

Publication number
KR20050108383A
KR20050108383A KR1020057016936A KR20057016936A KR20050108383A KR 20050108383 A KR20050108383 A KR 20050108383A KR 1020057016936 A KR1020057016936 A KR 1020057016936A KR 20057016936 A KR20057016936 A KR 20057016936A KR 20050108383 A KR20050108383 A KR 20050108383A
Authority
KR
South Korea
Prior art keywords
substituted
phenyl
alkyl
hydroxy
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057016936A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 브라이언트 바트
귀도 볼드
선규 김
티모시 마이클 램지
마이클 로이드 사비오
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20050108383A publication Critical patent/KR20050108383A/ko
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020057016936A 2003-03-11 2004-03-10 이소퀴놀린 유도체의 암 및 map 키나제 관련 질병의치료를 위한 용도 Ceased KR20050108383A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11
US60/453,624 2003-03-11

Publications (1)

Publication Number Publication Date
KR20050108383A true KR20050108383A (ko) 2005-11-16

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057016936A Ceased KR20050108383A (ko) 2003-03-11 2004-03-10 이소퀴놀린 유도체의 암 및 map 키나제 관련 질병의치료를 위한 용도

Country Status (22)

Country Link
EP (1) EP1603566B1 (https=)
JP (1) JP2006519807A (https=)
KR (1) KR20050108383A (https=)
CN (1) CN1758910A (https=)
AT (1) ATE421324T1 (https=)
AU (1) AU2004218914A1 (https=)
BR (1) BRPI0408257A (https=)
CA (1) CA2518530A1 (https=)
DE (1) DE602004019193D1 (https=)
ES (1) ES2318276T3 (https=)
HR (1) HRP20050788A2 (https=)
IS (1) IS8064A (https=)
MA (1) MA27724A1 (https=)
MX (1) MXPA05009687A (https=)
NO (1) NO20054647L (https=)
PL (1) PL1603566T3 (https=)
PT (1) PT1603566E (https=)
RU (1) RU2325159C2 (https=)
TN (1) TNSN05223A1 (https=)
TW (1) TW200501955A (https=)
WO (1) WO2004080464A1 (https=)
ZA (1) ZA200506571B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101336678B1 (ko) * 2005-07-26 2013-12-04 사노피 Rho-키나제 억제제로서의 사이클로헥실아민 이소퀴놀론유도체
KR20190133378A (ko) 2018-05-23 2019-12-03 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012377A (es) 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
JP2008517064A (ja) 2004-10-19 2008-05-22 アークル インコーポレイテッド P38mapキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
CN101160131A (zh) * 2005-02-25 2008-04-09 诺瓦提斯公司 Bcr-abl和raf抑制剂的药物组合产品
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CA2639416C (en) * 2007-09-11 2019-12-31 F. Hoffmann-La Roche Ag Diagnostic test for susceptibility to b-raf kinase inhibitors
EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
CN103038364A (zh) 2010-03-09 2013-04-10 达纳-法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
US9056855B2 (en) * 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
US20210275516A1 (en) * 2018-07-02 2021-09-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
ATE459616T1 (de) * 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GT200000158A (es) * 1999-09-28 2002-03-16 Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis.
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
US20030078271A1 (en) * 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
DE60239097D1 (de) * 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101336678B1 (ko) * 2005-07-26 2013-12-04 사노피 Rho-키나제 억제제로서의 사이클로헥실아민 이소퀴놀론유도체
KR20190133378A (ko) 2018-05-23 2019-12-03 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치

Also Published As

Publication number Publication date
JP2006519807A (ja) 2006-08-31
CN1758910A (zh) 2006-04-12
NO20054647D0 (no) 2005-10-10
MA27724A1 (fr) 2006-01-02
PT1603566E (pt) 2009-04-27
MXPA05009687A (es) 2005-10-20
WO2004080464A1 (en) 2004-09-23
EP1603566B1 (en) 2009-01-21
AU2004218914A1 (en) 2004-09-23
TNSN05223A1 (en) 2007-06-11
DE602004019193D1 (de) 2009-03-12
ATE421324T1 (de) 2009-02-15
HRP20050788A2 (en) 2006-12-31
RU2325159C2 (ru) 2008-05-27
IS8064A (is) 2005-10-10
CA2518530A1 (en) 2004-09-23
PL1603566T3 (pl) 2009-07-31
TW200501955A (en) 2005-01-16
ZA200506571B (en) 2006-07-26
ES2318276T3 (es) 2009-05-01
NO20054647L (no) 2005-12-09
BRPI0408257A (pt) 2006-03-07
RU2005131168A (ru) 2006-05-27
EP1603566A1 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
EP4081524B1 (en) Substituted heteroaryl compounds useful as t cell activators
ES2536313T3 (es) Imidazo[4,5-c]quinolinas como inhibidores de ADN–-PK
KR20070009530A (ko) 증식성 질환 치료에 유용한 raf-키나아제 억제제로서의1,4-이치환된 이소퀴놀린 유도체
US6608071B2 (en) Isoquinoline derivatives with angiogenesis inhibiting activity
KR20050108383A (ko) 이소퀴놀린 유도체의 암 및 map 키나제 관련 질병의치료를 위한 용도
JP2023513675A (ja) Kras変異に関連する癌の予防または治療のための医薬組成物
RU2707730C2 (ru) Пиридиновые соединения пладиенолида и способы применения
US20030130280A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
US20200377461A1 (en) Amine compound for inhibiting ssao / vap-1 and use thereof
JP2002541108A (ja) 炎症性疾患治療用フタラジン誘導体
WO2017106556A1 (en) Tank-binding kinase inhibitor compounds
AU2002360314A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
EA023642B1 (ru) Гетеробициклические производные в качестве ингибиторов hcv
AU2018309739B2 (en) Compounds, Compositions, and Methods for Treating T-cell Acute Lymphoblastic Leukemia
US20180117110A1 (en) Method of treating cancer
MX2012014638A (es) Pirazoloquinolinas.
US20230202992A1 (en) Pharmaceutical composition for preventing or treating small-cell lung cancer associated with ron mutants and method using same
AU2008200070A1 (en) Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases
KR20200030466A (ko) 7-하이드록시-4H-티에노[3,2-b]피리딘-5-온 유도체 및 그의 용도
WO2024260410A1 (zh) Otub2抑制剂及其在肿瘤免疫中的应用
WO2025085652A1 (en) Indole carboxamides useful as rac1 inhibitors
WO2025034569A9 (en) Sting inhibitors and methods of using thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050909

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090310

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110103

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20111004

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110103

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I